Mojtahedzadeh Mona, Lee Martin L, Friedman Theodore C
Martin Luther King, Jr. Outpatient Center (MLK-OC), Los Angeles, CA 90059, USA.
Martin Luther King, Jr. Outpatient Center (MLK-OC), Los Angeles, CA 90059, USA; Department of Biostatistics, Fielding School of Public Health, UCLA, Los Angeles, CA 90095, USA.
J Diabetes Complications. 2015 Nov-Dec;29(8):1248-52. doi: 10.1016/j.jdiacomp.2015.06.013. Epub 2015 Jul 2.
We studied the impact of continuing versus discontinuing pioglitazone on hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), and weight when starting bedtime insulin in patients with poor glycemic control.
We retrospectively analyzed data from a 13-month randomized control trial on 77 patients with type 2 diabetes mellitus (DM), who despite maximum doses of three oral diabetes medications (metformin, sulfonylurea and pioglitazone) had HbA1C levels above 7.5%. Patients were randomized to either continuing or discontinuing pioglitazone in addition to starting and up-titrating bedtime insulin. HbA1C, FPG, and weight were assessed at baseline, 3months, 7months and 13months with the differences from baseline for the two groups compared at each of the three time points using the Wilcoxon rank sum test.
We found that HbA1c was significantly lower at the 7-month (p=0.01) and 13-month time points (p=0.036), and FPG was significantly lower at all three time points in the group continuing pioglitazone compared with those discontinuing pioglitazone. Continuing pioglitazone resulted in a greater increase in weight at the 3-month (p=0.002), 7-month (p=0.0001) and 13-month (p=0.00003) time points. Patients with the lowest HbA1c (<8.2%) at baseline were more likely to benefit from continuing pioglitazone than those with higher baseline HbA1c. Patients who started insulin and discontinued pioglitazone had similar HbA1c, FPG and weight at the three time points as at baseline, suggesting that pioglitazone and bedtime insulin has similar glycemic effect in this population.
We conclude that in patients with uncontrolled type 2 DM, continuing pioglitazone while concurrently starting bedtime insulin within a 13-month period led to a significant decrease in both HbA1c and FPG levels compared with those who did not receive pioglitazone; however weight increased during this period.
我们研究了在血糖控制不佳的患者开始睡前胰岛素治疗时,继续使用与停用吡格列酮对糖化血红蛋白(HbA1c)、空腹血糖(FPG)和体重的影响。
我们回顾性分析了一项为期13个月的随机对照试验的数据,该试验涉及77例2型糖尿病(DM)患者,这些患者尽管使用了三种口服降糖药(二甲双胍、磺脲类药物和吡格列酮)的最大剂量,但糖化血红蛋白水平仍高于7.5%。除了开始并上调睡前胰岛素剂量外,患者被随机分为继续使用或停用吡格列酮两组。在基线、3个月、7个月和13个月时评估HbA1c、FPG和体重,并使用Wilcoxon秩和检验在三个时间点的每一个比较两组与基线的差异。
我们发现,与停用吡格列酮的组相比,继续使用吡格列酮的组在第7个月(p=0.01)和第13个月(p=0.036)时HbA1c显著降低,在所有三个时间点FPG均显著降低。继续使用吡格列酮在第3个月(p=0.002)、第7个月(p=0.0001)和第13个月(p=0.00003)时导致体重增加更多。基线时HbA1c最低(<8.2%)的患者比基线HbA1c较高的患者更有可能从继续使用吡格列酮中获益。开始胰岛素治疗并停用吡格列酮的患者在三个时间点的HbA1c、FPG和体重与基线时相似,这表明吡格列酮和睡前胰岛素在该人群中具有相似的血糖控制效果。
我们得出结论,在未控制的2型糖尿病患者中,在13个月内继续使用吡格列酮同时开始睡前胰岛素治疗,与未接受吡格列酮治疗的患者相比,HbA1c和FPG水平显著降低;然而在此期间体重增加。